BioScience Managers Translation Fund to spur Australian jobs and innovation

Melbourne, Australia 13 December, 2016 – BioScience Managers, one of Australia’s leading life sciences investment firms, has been awarded a $100 million investment licence for the Federal Government-backed Biomedical Translation Fund. BioScience Managers is one of three fund managers chosen to invest on behalf of the BTF and will be responsible for $100 million, half from […]

BioScience Managers partners with large UK Venture Capital Trust Fund

Agreement with Downing to launch a new Healthcare Offer for VCT investors A target raise of £10 million with investors able to make monthly contributions High demand likely, with fewer offers open to investment Portfolio to target dividends of at least 4 per cent pa (of net assets) from the fourth year onwards Melbourne, Australia […]

BioScience to lure big super – The Australian

Sarah-Jane Tasker – The Australian October 13, 2016 BioScience Managers is a small step away from running a $150 million fund under the government’s Biomedical Translation Fund, a move it says will revitalise the biotech sector. Jeremy Curnock-Cook, the managing director of Melbourne-based BioScience Managers, said the translation fund was an important initiative as it […]

BioScience Managers – New Bioscience Innovation Fund to Boost Australian Healthcare Startups

Melbourne, Australia, 3 October, 2016 – Australia’s innovative healthcare and biomedical research sectors are set for a massive boost with the launch of a new venture capital fund. “This is a breakthrough moment for many earlier stage, unlisted companies,” said BioScience Managers’ managing director Jeremy Curnock Cook. “Access to funding is vital in turning ideas […]

Jeremy Curnock Cook spoke to Sky News Business 27 Oct 2015

Jeremy Curnock Cook on Sky News Business (The Perrett Report) Oct 27, 2015. Additionally it can be downloaded here:

BioScience Managers $5M Cornerstone Investment in Saluda Medical

Potential breakthrough treatment for chronic pain Part of $10m capital raising BioScience Managers achieved a 24.7% IRR in its previous fund – top decile performance of international private equity and venture capital fund managers. 20 February 2015, Melbourne, Australia: Leading healthcare fund manager BioScience Managers has invested $5 million in novel chronic pain treatment company Saluda […]

BioScience Managers Capital Return on Healthcare Fund I Locks in 24.7% IRR for Investors

Outstanding capital return in final distribution for Australian Bioscience Fund I  Australia’s best performing biotech fund in recent years as per Cambridge Associates ratings 13 August 2014: AusBiotech Industry Spotlight here. Leading Australian healthcare fund manager Bioscience Managers has maintained its exceptional performance by returning capital to investors from its Australian Bioscience Fund I at 24.7% […]


7 January 2014: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for biotech stocks on the ASX in 2013 with an average gain of 53.6%* across the sector. These findings compare with the All Ordinaries index that increased by 14.7% over 2013 and theS&P/ASX 200 Health Care Index which increased 23.5% […]

BioScience Managers Banks on Growth in Anti-Infectives Market

Leading healthcare fund manager, BioScience Managers, has moved into the rapidly growing anti-infectives market with a US$1m investment into Bulletin Board-listed AmpliPhi Biosciences Corporation (APHB.PK). AmpliPhi has a proprietary library of bacteriophage, naturally occurring viruses which seek out and lethally target bacteria. Unaffected by antibiotic resistance these viruses are highly specific and have been proven […]

Bioscience Managers Supports Bioxyne Decision on Transaction

International life sciences investment group and major shareholder of Bioxyne, today backed the Bioxyne Board in their decision to withdraw from the company’s proposed transaction with Vitality Devices (See the announcement here). “During an extensive due diligence process, issues have come to light which indicate the transaction is now not an optimal investment for Bioxyne,” said BioScience […]